High Risk Of Recurrence clinical trials

Explore recruiting high risk of recurrence clinical trials.

Recruiting high risk of recurrence studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

High Risk Of Recurrence trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

GETUG 20 : Phase III randomised trial to evaluate the benefit of adjuvant hormonal treatment with leuprorelin acetate (Eligard® 45 mg) for 24 months after radical prostatectomy in patients with high risk of recurrence

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer: ENZARAD

Austria, Ireland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

DOSABEMA-Pharmacokinetic model of abemaciclib: correlation with severe diarrhea as the primary toxicity endpoint in patients with hormone receptor-positive localized breast cancer

France

Therapeutic use (Phase IV) EU CTIS Study details

PACHA-02_Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of recurrence

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Neoadjuvant AXITINIB plus AVELUMAB for patients with localized RCC and a moderate to high risk of recurrence (N17JAV)

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Neoadjuvant and adjuvant RIBOciclib and endocrine therapy for cLinicAlly high-RISk estrogen receptor-positive (ER+) and HER2-negative (HER2-) breast cancer (RIBOLARIS)

France, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

High Risk Of Recurrence trials by city

High Risk Of Recurrence in Toronto High Risk Of Recurrence in Vancouver High Risk Of Recurrence in Montreal High Risk Of Recurrence in Calgary High Risk Of Recurrence in Edmonton High Risk Of Recurrence in Ottawa High Risk Of Recurrence in Winnipeg High Risk Of Recurrence in Quebec City High Risk Of Recurrence in Hamilton High Risk Of Recurrence in Kitchener High Risk Of Recurrence in London High Risk Of Recurrence in Halifax High Risk Of Recurrence in New York High Risk Of Recurrence in Los Angeles High Risk Of Recurrence in Chicago High Risk Of Recurrence in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease